ZTlido (lidocaine patch 1.8%) / Sorrento 
Welcome,         Profile    Billing    Logout  
 0 Diseases   1 Trial   1 Trial   264 News 
  • ||||||||||  ZTlido (lidocaine patch 1.8%) / Sorrento
    Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis (Exhibit Hall) -  Jun 29, 2024 - Abstract #PAINWeek2024PAINWeek_114;    
    51.9% of LTS patients experienced either a decrease or discontinuation of opioid use in the post-prescription period compared to 45.5% of LP patients (Chi-square test, p=0.021). LTS patients had a non-significant change in pre- versus post-prescription median Morphine Milligram Equivalents (MME) (3.1% increase, Wilcoxon signed rank test, p=0.146); while LP patients experienced a significant increase in pre-versus post-prescription median MME (42.9% increase, Wilcoxon signed rank test, p< 0.001).
  • ||||||||||  ZTlido (lidocaine patch 1.8%) / Sorrento
    Decreased Cost Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis (Exhibit Hall) -  Jun 29, 2024 - Abstract #PAINWeek2024PAINWeek_113;    
    The median cost of office visits per LTS patient was $2518 pre-index and $2439 post-index (-3%, p=0.003), the median cost of ER/urgent care visits per LTS patient was $1574 pre-index and $1017 post-index (-35%, p=0.663), the median cost of outpatient visits per LTS patient was $2977 pre-index and $2984 post-index (+0.2%, p=0.906 ) and the median cost of pain procedures per LTS patient was $1150 pre-index and $1155 post-index (+0.4%, p=0.107).In contrast, the median cost of office visits per LP patient was $1862 pre-index and $1898 post-index (+2%, p=0.04), the median cost of ER/urgent care visits per LP patient was $2558 pre-index and $2501 post-index (-2%, p=0.624), the median cost of outpatient visits per LP patient was $3636 pre-index and $3926 post-index (+8%, p< 0.001), and the median cost of pain procedures per LP patient was $956 pre-index and $1024 post-index (+7%, p< 0.001). Conclusions/Implications for future research and/or clinical care: The overall cost reduction observed in the LTS cohort, and the cost increase observed in the LP cohort suggests that LTS may be associated with lower costs of care compared to LP due to better pain relief as a result of the superior adhesion qualities of LTS.
  • ||||||||||  lidocaine topical / Generic mfg.
    Journal:  Topical Delivery Systems Effectively Transport Analgesics to Areas of Localized Pain via Direct Diffusion. (Pubmed Central) -  Nov 25, 2023   
    An investigational TDS containing 108 mg lidocaine (SP-103, 5.4% lidocaine), a commercially available TDS containing 36 mg lidocaine (ZTlido, 1.8% lidocaine), and a topical pain relief gel (Pennsaid, 2% diclofenac) were tested...The data showed a clear contribution of diffusive transport to lidocaine concentration, with SP-103 5.4% resulting in a significantly higher lidocaine concentration in muscle tissue than commercially available ZTlido (p = 0.008). These results indicate that SP-103 5.4% is highly effective in delivering lidocaine into muscle tissue in areas of localized pain for the treatment of musculoskeletal pain disorders (e.g., lower back pain).
  • ||||||||||  ZTlido (lidocaine patch 1.8%) / Sorrento
    Trial completion, Trial completion date, Trial primary completion date:  CTS: Lidocaine Patch 1.8% for Moderate to Severe Pain From Carpal Tunnel Syndrome (clinicaltrials.gov) -  Jun 8, 2023   
    P4,  N=45, Completed, 
    These results indicate that SP-103 5.4% is highly effective in delivering lidocaine into muscle tissue in areas of localized pain for the treatment of musculoskeletal pain disorders (e.g., lower back pain). Unknown status --> Completed | Trial completion date: Mar 2021 --> May 2023 | Trial primary completion date: Dec 2020 --> May 2023
  • ||||||||||  ZTlido (lidocaine patch 1.8%) / Sorrento
    New P1 trial:  Adhesion of Lidocaine Topical System 1.8% (clinicaltrials.gov) -  Mar 18, 2020   
    P1,  N=54, Completed,